WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H576888
CAS#: 862543-54-2 (citrate)
Description: Maropitant citrate anhydrous is a neurokinin (NK1) receptor antagonist.
Hodoodo Cat#: H576888
Name: Maropitant citrate anhydrous
CAS#: 862543-54-2 (citrate)
Chemical Formula: C38H48N2O8
Exact Mass: 660.34
Molecular Weight: 660.810
Elemental Analysis: C, 69.07; H, 7.32; N, 4.24; O, 19.37
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 862543-54-2 (citrate) 359875-09-5 (citrate hydrate) 147116-67-4 (free base)
Synonym: Maropitant citrate anhydrous
IUPAC/Chemical Name: (2S,3S)-2-benzhydryl-N-(5-(tert-butyl)-2-methoxybenzyl)quinuclidin-3-amine 2-hydroxypropane-1,2,3-tricarboxylate
InChi Key: XDZPFSKCXRGRIO-PNXDLZEOSA-N
InChi Code: InChI=1S/C32H40N2O.C6H8O7/c1-32(2,3)27-15-16-28(35-4)26(21-27)22-33-30-25-17-19-34(20-18-25)31(30)29(23-11-7-5-8-12-23)24-13-9-6-10-14-24;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-16,21,25,29-31,33H,17-20,22H2,1-4H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t30-,31-;/m0./s1
SMILES Code: COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)(C)C.OC(=O)CC(O)(CC(=O)O)C(=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 660.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Johnson RA. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone. Vet Anaesth Analg. 2013 Dec 16. doi: 10.1111/vaa.12120. [Epub ahead of print] PubMed PMID: 24330310.
2: Niyom S, Boscan P, Twedt DC, Monnet E, Eickhoff JC. Effect of maropitant, a neurokinin-1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats. Vet Anaesth Analg. 2013 Jul;40(4):425-31. doi: 10.1111/vaa.12017. Epub 2013 Feb 13. PubMed PMID: 23406526.
3: Lesman SP, Boucher JF, Grover GS, Cox SR, Bidgood TL. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2013 Oct;36(5):462-70. doi: 10.1111/jvp.12027. Epub 2012 Nov 20. PubMed PMID: 23167698.
4: Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013 Jan;40(1):28-34. doi: 10.1111/j.1467-2995.2012.00788.x. Epub 2012 Oct 20. PubMed PMID: 23082784.
5: Boscan P, Monnet E, Mama K, Twedt DC, Congdon J, Steffey EP. Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs. Am J Vet Res. 2011 Dec;72(12):1576-9. doi: 10.2460/ajvr.72.12.1576. PubMed PMID: 22126683.
6: Alvillar BM, Boscan P, Mama KR, Ferreira TH, Congdon J, Twedt DC. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39(2):201-5. doi: 10.1111/j.1467-2995.2011.00670.x. Epub 2011 Nov 22. PubMed PMID: 22103569.
7: Mathis A, Lee K, Alibhai HI. The use of maropitant to prevent vomiting induced by epidural administration of preservative free morphine through an epidural catheter in a dog. Vet Anaesth Analg. 2011 Sep;38(5):516-7. doi: 10.1111/j.1467-2995.2011.00645.x. PubMed PMID: 21831059.
8: Williams-Fritze MJ, Carlson Scholz JA, Zeiss C, Deng Y, Wilson SR, Franklin R, Smith PC. Maropitant citrate for treatment of ulcerative dermatitis in mice with a C57BL/6 background. J Am Assoc Lab Anim Sci. 2011 Mar;50(2):221-6. PubMed PMID: 21439216; PubMed Central PMCID: PMC3061423.
9: Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med. 2010 Nov-Dec;24(6):1452-7. doi: 10.1111/j.1939-1676.2010.0611.x. Epub 2010 Oct 12. PubMed PMID: 21039869.
10: Narishetty ST, Galvan B, Coscarelli E, Aleo M, Fleck T, Humphrey W, McCall RB. Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection. Vet Ther. 2009 Fall;10(3):93-102. PubMed PMID: 20037963.
